gip/glp-1 receptor agonist New strategies for the treatment of obesity and metabolic dysfunctions Spatiotemporal GLP-1 and GIP receptor
Description
Middle East & Africa Fire Safety Systems & Equipment Market Click here to view more
doi: 10.1523/JNEUROSCI.0115-14.2014 [DOI] [PMC free article] [PubMed] [Google Scholar] 157.Antonsen KK, Klausen MK, Brunchmann AS, et al
SGLT2 inhibitors have shown salutary cardiovascular and renal benefits in patients with T2D and signified a new era, in which antidiabetic therapies should be based on end-organ protection and patient comorbidities, rather than aiming only on decreasing blood glucose concentration [8891]
Addressing Mental Health Concerns Integrating psychological support into obesity treatment plans can help manage emotional well-being
